Kathryn Leicht

Kathryn Leicht is a patent litigation attorney at Weil, Gotshal & Manges LLP, specializing in complex disputes within the pharmaceutical and biotechnology sectors. Her practice is primarily focused on representing plaintiffs, particularly in cases involving biologics and biosimilars.

Leicht has played a significant role as lead counsel for Regeneron Pharmaceuticals, Inc. in its extensive patent litigation, including the case Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc. She is also actively involved in the broader In re Aflibercept Patent Litigation multidistrict litigation, representing Regeneron in disputes concerning its Eylea product against various biosimilar manufacturers, such as Amgen Inc. and Mylan. A notable outcome includes a detailed post-trial opinion issued in December 2023, where a Regeneron patent was found valid and infringed in one of the cases against Mylan.

Information regarding her specific PTAB/IPR experience and educational background is not readily available in the publicly accessible sources reviewed.